Aptose Biosciences
APTO
APTO was delisted on the 1st of April, 2025.
47 hedge funds and large institutions have $13.4M invested in Aptose Biosciences in 2022 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 11 increasing their positions, 11 reducing their positions, and 8 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 11
1.73% less ownership
Funds ownership: 26.73% → 25.01% (-1.7%)
4% less funds holding
Funds holding: 49 → 47 (-2)
13% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 8
63% less capital inflows, than outflows
Capital inflows: $531K | Capital outflows: $1.44M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Sigma Planning
Ann Arbor,
Michigan
|
+$102K |
| 2 |
TI
Telemetry Investments
New York
|
+$59.6K |
| 3 |
Millennium Management
New York
|
+$56.9K |
| 4 |
Annandale Capital
Dallas,
Texas
|
+$53.7K |
| 5 |
Formidable Asset Management
Cincinnati,
Ohio
|
+$53.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nantahala Capital Management
New Canaan,
Connecticut
|
-$499K |
| 2 |
Sanders Morris Harris
Houston,
Texas
|
-$377K |
| 3 |
P.A.W. Capital
Greenwich,
Connecticut
|
-$336K |
| 4 |
Morgan Stanley
New York
|
-$45.9K |
| 5 |
Carlson Capital
Dallas,
Texas
|
-$29.8K |
APTO Hedge Fund Activity: Q4 2022 in Review
47 of the 6,245 institutional investors tracked by Wall St. Rank reported a position in Aptose Biosciences (APTO) for Q4 2022, worth a combined $13.4M — down 8.8% from $14.7M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of APTO and 7 opened new positions — a net loss of 1 holder — while 11 trimmed existing stakes and 11 added.
The largest buyer was Sigma Planning, adding an estimated $102K. The largest seller was Nantahala Capital Management, cutting an estimated $499K.
- 47 institutional investors held Aptose Biosciences (APTO) as of Q4 2022, down from 49 in Q3 2022.
- Funds reported $13.4M of Aptose Biosciences stock for Q4 2022, down 8.8% quarter-over-quarter.
- 7 funds opened new Aptose Biosciences positions in Q4 2022 and 8 closed out, a net change of -1 holder.
- The largest Aptose Biosciences buyer in Q4 2022 was Sigma Planning, an estimated $102K added.
- The largest Aptose Biosciences seller in Q4 2022 was Nantahala Capital Management, an estimated $499K sold.
Based on aggregated 13F filings for Q4 2022.